Showing 811-820 of 2392 results for "".
- Positive Phase 2 Results for Evobrutinib Treatment of MS and Initiation of Phase 3 Trialshttps://practicalneurology.com/news/positive-phase-2-results-for-evobrutinib-treatment-of-ms-and-initiation-of-phase-3-trials/2469014/At the European Committee on Research and Treatment in Multiple Sclerosis (ECTRIMS) Congress in Stockholm, Sweden September 11-13, 2019, data from a phase 2 trial (NCT02975349) of evobrutinib (EMD Serono, Rockland, MD) for treatment of
- Eye Tracking Technology Detects Traumatic Brain Injury With Sensitivity and Specificityhttps://practicalneurology.com/news/eye-tracking-technology-detects-traumatic-brain-injury-with-sensitivity-and-specificity/2469003/Research findings published in Concussion show that measurement of horizontal saccades with eye-tracking technology (Brain Health EyeQ; RightEye, Bethesda, MD) has a 77% sensitivity and 78% specificity for i
- Research Leaders Recognized at the 2025 MDA Clinical & Scientific Conferencehttps://practicalneurology.com/news/research-leaders-recognized-at-the-2025-mda-clinical-scientific-conference/2473814/The Muscular Dystrophy Association (MDA) recognized 2 legacy award recipients at the 2025 MDA Clinical & Scientific Conference. The awardees were honored based on their significant contributions to clinical research and community advocacy. The 2025 MDA Legacy Award for Achie
- MDA Provides COVID-19 Recommendations for People with Neuromuscular Conditions that Also Apply to Other Neurologic Conditionshttps://practicalneurology.com/news/mda-provides-covid-19-recommendations-for-people-with-neuromuscular-conditions-that-also-apply-to-other-neurologic-conditions/2469188/The Muscular Dystrophy Association (MDA) has provided recommendations for people in the neuromuscular community regarding the current COVID-19 pandemic. Noting that current guidelines from public health agencies focus on travelers, specific age group
- FDA Rejects Application for Gene Therapy for Hunter Syndromehttps://practicalneurology.com/news/fda-rejects-application-for-gene-therapy-for-hunter-syndrome/2485648/The Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the Biologics License Application (BLA) for RGX-121 (clemidsogene lanparvovec; REGENXBIO, Rockville, MD), meaning that, at this time, the FDA will not approve the investigational gene therapy for mucopolysaccha
- Director of the National Institute of Neurological Disorders and Stroke Oustedhttps://practicalneurology.com/news/director-of-the-national-institute-of-neurological-disorders-and-stroke-ousted/2485145/The contract for Walter Koroshetz, MD, as Director of the National Institute of Neurological Disorders and Stroke (NINDS) has not been renewed, ending his leadership of the institute after 10 years. Dr. Koroshetz’s departure comes despite a positive internal review and a recommendation for reappo
- Prof. Ludwig Kappos Recognized for His Lifetime Achievement in Multiple Sclerosis Research at ECTRIMS 2025https://practicalneurology.com/news/prof-ludwig-kappos-recognized-for-his-lifetime-achievement-in-multiple-sclerosis-research-at-ectrims-2025/2483561/At the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Ludwig Kappos, MD, Dipl Psych, FEAN, FAAN was recognized as the recipient of the 2025 Charcot Award. According to ECTRIMS, the Charcot Award, which is presented by the Multiple Sclerosis Int
- Studies Evaluate the Reweighting of Parkinson Disease Assessment Tools for Improved Sensitivity and Efficiencyhttps://practicalneurology.com/news/studies-evaluate-the-reweighting-of-parkinson-disease-assessment-tools-for-improved-sensitivity-and-efficiency/2474181/Reweighting the Movement Disorder Society–Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) and other measures may provide greater sensitivity and responsiveness in assessing motor and functional decline in people with Parkinson disease (PD), according to the results of 2 studies presented at
- Continuous, Subcutaneous Apomorphine Infusion Device Approved for Parkinson’shttps://practicalneurology.com/news/continuous-subcutaneous-apomorphine-infusion-device-approved-for-parkinsons/2473778/The Food and Drug Administration (FDA) has approved the wearable Onapgo (apomorphine hydrochloride; Supernus Pharmaceuticals, Rockville, MD) subcutaneous injection device to treat motor fluctuations in adults with advanced Parkinson disease (PD). Onapgo enables continuous apomorphine infusion dur
- National Institutes of Health Allege Research Misconduct by Prominent Neuroscientist and Investigator of α-Synuclein in PD and ADhttps://practicalneurology.com/news/nih-alleges-research-misconduct-by-prominent-neuroscientist-and-investigator-of-a-synuclein-in-pd-and-ad/2470601/Eliezer Masliah, MD, director of the National Institutes of Aging (NIA) neuroscience division, has been accused of research misconduct via the falsification, duplication, and manipulation of images, particularly western blot images. Much of Dr. Masliah’s work focuses on the role of &al